Mifepristone Linepharma (Mifepristone)

Mifepristone works by selectively binding to progesterone receptors, preventing progesterone from activating its target cells. This antagonism leads to breakdown of the uterine lining and stimulates uterine contractions, while also inhibiting progesterone‑driven growth in adrenal tissue, fibroids, and ectopic endometrium.

The dosage of Mifepristone Linepharma is determined by the prescribing healthcare professional based on the specific indication, patient characteristics, and clinical guidelines. Patients should follow the exact regimen provided by their prescriber.

Mifepristone is classified as Pregnancy Category X, meaning it is contraindicated in an ongoing pregnancy except when used for termination under medical supervision. It is also not recommended during breastfeeding because it may pass into breast milk and affect the infant.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

The most common alternative in medical abortion regimens is misoprostol, which is a prostaglandin analogue that induces uterine contractions. Mifepristone acts first by blocking progesterone, creating a more receptive uterine environment, while misoprostol completes the process by stimulating contractions. The combination is often more effective than misoprostol alone.

Mifepristone Linepharma tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

The medication is administered orally as a tablet, usually taken with a glass of water under the supervision of a qualified healthcare provider. The exact timing and any subsequent medications are determined by the prescriber.

Serious risks include heavy or prolonged vaginal bleeding, infection, severe allergic reactions (including anaphylaxis), liver toxicity, and adrenal insufficiency. Patients should seek immediate medical attention if they experience any of these symptoms.

Mifepristone is contraindicated in individuals with known hypersensitivity to the drug, those who are pregnant and not seeking termination, patients with chronic adrenal failure, uncontrolled severe asthma, or those taking certain interacting medications such as strong CYP3A4 inducers without medical guidance.